Zanamivir Articles
Europe’s CHMP backs Sanofi Pasteur’s Humenza and GSK’s Votrient; gives opinions on other products
22 February 2010
UK Appeal Court invalidates HGS/GlaxoSmithKline lupus drug patent; Simcere cleared to manufacture and sell zanamivir in China
11 February 2010
GlaxoSmithKline to refocus some research and seek efficiencies, despite posting huge 4th-qtr 2009 profits rise; applause from Science Minister
5 February 2010
Scam artists in USA cash in on Swine flu, says Consumer Reports
18 November 2009
Biota acquires antibacterial assets of Prolysis and of MaxThera
12 November 2009
GlaxoSmithKline’s pandemic H1N1 vaccine cleared by US FDA; firm donates 50M doses to WHO
12 November 2009
GlaxoSmithKline beats forecasts with 3rd quarter2009 profits leaping 34%, despite generic competition
28 October 2009
Highlights of research presented at ICAAC
15 September 2009
Research casts doubt on the policy of giving antiviral drugs to children for swine flu
11 August 2009
Australian govt stockpiles additional Relenza
29 May 2009
US FTC to check 10 web sites over bogus H1N1
28 May 2009
Simcere seeking appro for generic zanamavir
7 May 2009
EMEA prepares for pandemic vaccines
1 May 2009
UK gets warning on counterfeit swine flu drugs
30 April 2009
Qiagen's solution to swine flu surveillance
29 April 2009
Biota's six-month profit jumps 31% on GSK deal
2 March 2009
UK gov orders 10.6M doses of Relenza
9 February 2009
UPDATE: Roche's Tamiflu ineffective against 2009 primary flu strain; GSK has alternative
12 January 2009
Roche's Tamiflu ineffective against primary flu strain for this season; GSK's Relenza set to take over
12 January 2009
UNSIC warns of gaps in flu readiness
20 October 2008
UK's NICE says "Yes" to some drugs
29 September 2008
Japan MHLW budget up 3.7% to $211B
15 September 2008
GSK offers employers Relenza flu vaccine option
8 September 2008
Biota defends Relenza settlement with GSK
1 September 2008
GSK settles Relenza dispute for A$20M
28 July 2008
US FDA panel calls for label revisions on Tamiflu and Relenza
3 December 2007
US FDA to review drugs' effects on children
3 December 2007
Biota's flu drug enters Ph II trials
26 November 2007
Biota updates GSK Relenza suit
6 August 2007
"Great potential" for generics in Australia
14 May 2007
Biota may up claim against GSK
9 April 2007
UK's bird flu vacc stocks "should rise 600%"
19 February 2007
Study finds antivirals effectively curb flu virus and are valuable in managing seasonal flu
22 January 2007
Canadian govt orders 5.5M courses of Relenza
20 November 2006
Simcere to make and sell cheap Relenza
9 October 2006
GSK's Relenza cleared in EU for use in adults and children
4 September 2006
Court sets trial date for Biota vs GSK
4 September 2006
First-stage NIH award for Australia's Biota
14 August 2006
Japan says asian flu a designated disease
1 May 2006
US FDA prohibits poultry antivirals
27 March 2006
US HHS buys more antivirals
13 March 2006
Strong avian flu data on Ampligen/Alferon
27 February 2006
GSK to increase Relenza production
6 February 2006
Lancet: Tamiflu bad choice against seasonal flu
30 January 2006
GSK to benefit from H5N1 flu pandemic contingency plans?
22 August 2005
Biota values damage claims against GSK
8 August 2005
Biota benefits from flu vacc shortage
22 November 2004
US HHS Sec seeks to assure on flu vaccine
1 November 2004
Biota goes ahead with suit against GSK
5 July 2004
Biota sues GSK for failure over Relenza
10 May 2004
Israel studies worldwide politics of pharmaceutical reimbursement
23 February 2004
Australia's Biota being courted by asset stripper
31 March 2003
UK NICE issues flu and diabetes guidances
3 March 2003
Flu drug shortage hits Japan, Chugai issues apology
10 February 2003
Roche's Tamiflu launched in UK
3 February 2003
BioCryst drops flu drug in Phase III
1 July 2002
NICE "should appraise innovative new drugs a year before launch"
4 February 2002
UK parliament
28 January 2002
UK parliamentary inquiry hears credibility of NICE guidance
21 January 2002
Poor Relenza sales hurting Biota
8 November 2001
Stock Commentary - Tokyo
8 November 2001
Tokyo pharma stocks - week to November 5
7 November 2001
Biota predicting downturn in profits
30 May 2001
J&J ends flu-drug deal with BioCryst
3 May 2001
US HMOs reveal their most-accepted drugs
5 April 2001
GlaxoSmithKline starts life in 2001 on a strong financial footing
21 February 2001
UK GPs prescribing fewer antibiotics
16 February 2001
Roche plans Tamiflu launch in Japan soon
23 January 2001
Tamiflu approved in USA for flu in kids
15 December 2000
Infertility next targets for the UK's NICE
6 December 2000
Stock Commentary - Europe
30 November 2000
ABPI criticizes NICE delayin Relenza issue
22 November 2000
Roche wins Tamiflu prevention use in USA
21 November 2000
Roche's Tamiflu OKed in Japan
16 November 2000
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
